{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+of+Uterus&page=2",
    "query": {
      "condition": "Malignant Neoplasm of Uterus",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 134,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+of+Uterus&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+of+Uterus&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T14:34:33.260Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01154452",
      "title": "Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Alveolar Soft Part Sarcoma",
        "Adult Angiosarcoma",
        "Adult Desmoplastic Small Round Cell Tumor",
        "Adult Epithelioid Hemangioendothelioma",
        "Adult Epithelioid Sarcoma",
        "Adult Extraskeletal Myxoid Chondrosarcoma",
        "Adult Extraskeletal Osteosarcoma",
        "Adult Fibrosarcoma",
        "Adult Leiomyosarcoma",
        "Adult Liposarcoma",
        "Adult Malignant Mesenchymoma",
        "Adult Malignant Peripheral Nerve Sheath Tumor",
        "Adult Rhabdomyosarcoma",
        "Adult Synovial Sarcoma",
        "Adult Unclassified Pleomorphic Sarcoma",
        "Chondrosarcoma",
        "Clear Cell Sarcoma of the Kidney",
        "Conjunctival Kaposi Sarcoma",
        "Dermatofibrosarcoma Protuberans",
        "Gastrointestinal Stromal Tumor",
        "Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Metastatic Osteosarcoma",
        "Ovarian Sarcoma",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Kaposi Sarcoma",
        "Recurrent Osteosarcoma",
        "Recurrent Uterine Corpus Sarcoma",
        "Small Intestine Leiomyosarcoma",
        "Stage III Adult Soft Tissue Sarcoma",
        "Stage III Uterine Sarcoma",
        "Stage IV Adult Soft Tissue Sarcoma",
        "Stage IV Uterine Sarcoma",
        "Unclassified Pleomorphic Sarcoma of Bone"
      ],
      "interventions": [
        {
          "name": "Gamma-Secretase Inhibitor RO4929097",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Vismodegib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2010-06",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2018-08-15",
      "last_synced_at": "2026-10-02T14:34:33.260Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01154452"
    },
    {
      "nct_id": "NCT00055705",
      "title": "PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "PV701",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-04-26",
      "last_synced_at": "2026-10-02T14:34:33.260Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00055705"
    },
    {
      "nct_id": "NCT00502203",
      "title": "Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mixed Tumor, Mullerian"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 23,
      "start_date": "2001-08",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2016-05-09",
      "last_synced_at": "2026-10-02T14:34:33.260Z",
      "location_count": 4,
      "location_summary": "Loma Linda, California • Orlando, Florida • Houston, Texas",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00502203"
    },
    {
      "nct_id": "NCT05786456",
      "title": "e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Malignant Female Reproductive System Neoplasm",
        "Stage III Cervical Cancer AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Uterine Corpus Cancer AJCC v8",
        "Stage III Vaginal Cancer AJCC v8",
        "Stage III Vulvar Cancer AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Uterine Corpus Cancer AJCC v8",
        "Stage IV Vaginal Cancer AJCC v8",
        "Stage IV Vulvar Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Discussion",
          "type": "PROCEDURE"
        },
        {
          "name": "Informational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Media Intervention",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Telephone-Based Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 23,
      "start_date": "2024-07-19",
      "completion_date": "2026-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-10-02T14:34:33.260Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05786456"
    },
    {
      "nct_id": "NCT03508570",
      "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Peritoneal Neoplasm",
        "Malignant Retroperitoneal Neoplasm",
        "Metastatic Cervical Carcinoma",
        "Metastatic Endometrial Carcinoma",
        "Metastatic Fallopian Tube Carcinoma",
        "Metastatic Malignant Female Reproductive System Neoplasm",
        "Metastatic Ovarian Carcinoma",
        "Metastatic Primary Peritoneal Carcinoma",
        "Peritoneal Carcinomatosis",
        "Platinum-Refractory Fallopian Tube Carcinoma",
        "Platinum-Refractory Malignant Female Reproductive System Neoplasm",
        "Platinum-Refractory Ovarian Carcinoma",
        "Platinum-Refractory Primary Peritoneal Carcinoma",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Malignant Female Reproductive System Neoplasm",
        "Platinum-Resistant Ovarian Carcinoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Recurrent Cervical Carcinoma",
        "Recurrent Endometrial Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Malignant Female Reproductive System Neoplasm",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Stage IV Fallopian Tube Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Primary Peritoneal Cancer AJCC v8",
        "Stage IVA Fallopian Tube Cancer AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVA Primary Peritoneal Cancer AJCC v8",
        "Stage IVB Cervical Cancer AJCC v8",
        "Stage IVB Fallopian Tube Cancer AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8",
        "Stage IVB Primary Peritoneal Cancer AJCC v8",
        "Stage IVB Uterine Corpus Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacokinetic Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 26,
      "start_date": "2018-09-21",
      "completion_date": "2024-11-11",
      "has_results": false,
      "last_update_posted_date": "2025-05-22",
      "last_synced_at": "2026-10-02T14:34:33.260Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03508570"
    },
    {
      "nct_id": "NCT04660929",
      "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive",
        "Adenocarcinoma",
        "Bile Duct Cancer",
        "Biliary Tract Cancer",
        "Bladder Cancer",
        "Breast Cancer",
        "Breast Neoplasm",
        "Carcinoma, Ductal",
        "Carcinoma, Hepatocellular",
        "Cancer",
        "Lung Cancer, Non-Small-Cell",
        "Carcinoma, Ovarian Epithelial",
        "Carcinoma, Small Cell",
        "Carcinoma, Squamous",
        "Carcinoma, Transitional Cell",
        "Colorectal Cancer",
        "Esophagogastric Junction Neoplasms",
        "Inflammatory Breast Cancer",
        "Stomach Neoplasms",
        "Malignant Neoplasms",
        "Ovarian Neoplasms",
        "Pancreatic Cancer",
        "HER2-positive Solid Tumors",
        "HER2-positive Breast Cancer",
        "HER2-positive Gastric Cancer",
        "HER-2 Protein Overexpression",
        "HER-2 Gene Amplification",
        "Prostate Cancer",
        "Head and Neck Cancer",
        "Endometrial Cancer",
        "Lung Cancer, Small Cell"
      ],
      "interventions": [
        {
          "name": "CT-0508",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Carisma Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2021-02-02",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-12-18",
      "last_synced_at": "2026-10-02T14:34:33.260Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04660929"
    },
    {
      "nct_id": "NCT04266886",
      "title": "Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Malignant Female Reproductive System Neoplasm",
        "Recurrent Malignant Female Reproductive System Neoplasm",
        "Metastatic Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Hypnotherapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 152,
      "start_date": "2018-09-11",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-02T14:34:33.260Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04266886"
    },
    {
      "nct_id": "NCT01364844",
      "title": "Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Colorectal Cancer",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "DS-7423",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2011-07",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2014-02-25",
      "last_synced_at": "2026-10-02T14:34:33.260Z",
      "location_count": 3,
      "location_summary": "Detroit, Michigan • New York, New York • Nashville, Tennessee",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01364844"
    },
    {
      "nct_id": "NCT04329494",
      "title": "PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Clinical Stage IVA Gastric Cancer AJCC v8",
        "Clinical Stage IVB Gastric Cancer AJCC v8",
        "Malignant Uterine Neoplasm",
        "Metastatic Appendix Carcinoma",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Gastric Carcinoma",
        "Metastatic Malignant Neoplasm in the Peritoneum",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Ovarian Carcinoma",
        "Pathologic Stage IV Gastric Cancer AJCC v8",
        "Peritoneal Carcinomatosis",
        "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8",
        "Stage IV Appendix Carcinoma AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Uterine Corpus Cancer AJCC v8",
        "Stage IVA Appendix Carcinoma AJCC v8",
        "Stage IVA Colorectal Cancer AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVA Uterine Corpus Cancer AJCC v8",
        "Stage IVB Appendix Carcinoma AJCC v8",
        "Stage IVB Colorectal Cancer AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8",
        "Stage IVB Uterine Corpus Cancer AJCC v8",
        "Stage IVC Appendix Carcinoma AJCC v8",
        "Stage IVC Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Intraperitoneal Chemotherapy",
          "type": "DEVICE"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Mitomycin",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2020-08-21",
      "completion_date": "2028-01-05",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-10-02T14:34:33.260Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Jacksonville, Florida • Greenlawn, New York",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Greenlawn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04329494"
    },
    {
      "nct_id": "NCT04634617",
      "title": "Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Endometrial Carcinoma",
        "Malignant Uterine Neoplasm",
        "Uterine Corpus Cancer",
        "Uterine Corpus Sarcoma"
      ],
      "interventions": [
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 310,
      "start_date": "2020-01-09",
      "completion_date": "2027-04-11",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-10-02T14:34:33.260Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04634617"
    }
  ]
}